Los Angeles, USA, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Respiratory Syncytial Virus Infection Pipeline: Insights into Clinical Trial Landscape, Key Pharma Players, Emerging Therapies with Novel MoAs, and Dynamics Shaping the Pipeline Landscape | DelveInsight
A vaccine in the Respiratory Syncytial Virus Infection Pipeline presents a cost-effective solution to reducing the burden of RSV, as current options for both prevention and treatment are limited with currently no licensed vaccines available.
DelveInsight's 'Respiratory Syncytial Virus (RSV) Infection Pipeline Insights' report provides exhaustive global coverage of the available therapies, Respiratory Syncytial Virus drug profiles, emerging therapies in different phases of clinical development, key companies working to advance the Respiratory Syncytial Virus Infection Pipeline drugs, and future potential of the Respiratory Syncytial Virus Infection Pipeline domain. It also includes the Respiratory Syncytial Virus therapeutics assessment by product type, stage, mechanism of action, and molecule type.
Some of the significant pointers taken from the Respiratory Syncytial Virus Infection Pipeline report:
- DelveInsight's analysis depicts a robust Respiratory Syncytial Virus Infection Pipeline with 50+ active players in the domain working on 50+ pipeline therapies.
- Key Respiratory Syncytial Virus Infection Pipeline therapies such as RSV-F, V-306, CodaVax-RSV, mRNA-1345, MV-012-968, RV521, BARS13, EDP-938, MEDI8897, RSV MAT, RSVpreF, JNJ-53718678, RSV vaccine, ALVR106, V-306, CodaVax-RSV, mRNA-1345, Research program: sirtuin targeted therapeutics for respiratory viral infections and others are under different phases of clinical trials for Respiratory Syncytial Virus (RSV).
- Virometix, ReViral Ltd, Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. Codagenix, Inc, ModernaTX, Inc., Meissa Vaccines, Inc., Vaxart, Inc., Enanta Pharmaceuticals, MedImmune LLC (AstraZeneca), GlaxoSmithKline, Pfizer, Janssen Sciences Ireland UC, Icosavax, Inc., Ark Biosciences, Bavarian Nordic, Kidswell Bio, Evrys Bio, ReViral Ltd, Sanofi, Daiichi Sankyo, Codagenix, Inc., Cidara Therapeutics, clover biopharmaceuticals, Alios BioPharma, Allovir, Airway Therapeutics, and others are under different phases of clinical trials for Respiratory Syncytial Virus.
- The RSVpreF (Pfizer) vaccine candidate is based on the prefusion form of the RSV fusion protein. The vaccine works by stimulating the production of serum anti-F immunoglobulin G in the pregnant woman, which is transferred to the fetus across the placenta and provides protection for the first six months of life when the risk of hospitalization is highest.
- Enanta has selected EDP-938, a potent non-fusion inhibitor of both RSV-A and RSV-B activity, as its first development candidate for RSV.
- IVX-121 and IVX-A12 are the two vaccine candidates being developed by Icosavax, Inc. IVX-121 target Respiratory Syncytial Virus, a major cause of viral pneumonia for which no vaccine has been FDA approved.
- ResVax is our aluminum-adjuvanted RSV F vaccine for infants via maternal immunization. The Bill & Melinda Gates Foundation (BMGF) has supported the Prepare trial for ResVax through a grant of up to $89.1 million; BMGF continues to financially support our efforts to conduct certain follow-up analyses of the Phase III data.
- In October 2020, Moderna, Inc., regained all rights to the respiratory syncytial virus (RSV) vaccine (mRNA-1172) from Merck, known as MSD outside the United States and Canada, including rights to develop RSV vaccines for adult populations. mRNA-1172, which uses a Merck lipid nanoparticle for delivery, entered Phase 1 development in 2019. Under the terms of the agreement, Merck will complete the Phase 1 study and transition the program to Moderna.
- The development of V-306 Virometix offers a differentiated approach to RSV vaccine development. In Phase I clinical trial, V-306 demonstrated strong, durable, specific, and protective immune responses, with minimal risk of vaccine-associated enhanced respiratory disease.
- Meissa is developing MV-012-968, an intranasal (needle-free), adjuvant-free, live-attenuated vaccine candidate, to protect infants and at-risk older adults from RSV. MV-012-968 is currently in a Phase IIa, randomized, double-blind, placebo-controlled challenge study designed to evaluate the safety and prophylactic efficacy of the Meissa vaccine against symptomatic RSV infection
Request Sample to know more about the pipeline therapies @ Respiratory Syncytial Virus Infection Pipeline Insights
The Respiratory Syncytial Virus Infection Pipeline report offers comprehensive insights into the assessment of active pipeline products, inactive products analysis (dormant and terminated), comparative analysis of clinical and non-clinical stage RSV products, and understanding of the limitations and challenges with regard to the development of therapies for Respiratory Syncytial Virus.
Respiratory Syncytial Virus Overview
Respiratory Syncytial Virus causes respiratory infections throughout life, with infants in the first months of life, severely immune-compromised adults, and the elderly especially susceptible to developing severe lower respiratory tract disease or death. The virus is the most common cause of lower respiratory tract infections (LRTI) and the leading viral cause of severe lower respiratory tract disease in infants and young children globally.
Learn more about the disease, treatments, and pipeline therapies @ Respiratory Syncytial Virus Infection Pipeline Assessment
Respiratory Syncytial Virus Infection Pipeline Drugs
| Drug | Company | Phase | MoA | RoA |
| RSV-F | Novavax | III | Immunostimulants | Intramuscular |
| MEDI8897 | MedImmune LLC (AstraZeneca) | III | Immunostimulants | Intramuscular |
| RSVpreF | Pfizer | III | Immunostimulants | Intramuscular |
| JNJ-53718678 | Janssen Sciences Ireland UC | III | Viral fusion protein inhibitors | Oral |
| RSV MAT | GlaxoSmithKline | III | Immunostimulants | Intramuscular |
| MV-012-968 | Meissa Vaccines, Inc. | II | Immunostimulants | Intranasal |
| RV521 | ReViral Ltd | II | Viral fusion protein inhibitors; Virus replication inhibitors | Oral |
| BARS13 | Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. | II | Immunostimulants | Intramuscular |
| EDP-938 | Enanta Pharmaceuticals | II | Viral fusion protein inhibitors | Oral |
| MVA-mBN294B | Bavarian Nordic | II | Immunostimulants | Intramuscular |
| RSV vaccine | Sanofi | I/II | Immunostimulants | Intranasal |
| ALVR106 | Allovir | I/II | Immunologic cytotoxicity; T lymphocyte replacements | NA |
| V-306 | Virometix | I | Immunostimulants | Intramuscular |
| CodaVax-RSV | Codagenix, Inc | I | CD8 positive T lymphocyte stimulants; Immunostimulants | Intranasal |
| mRNA-1345 | ModernaTX, Inc. | I | Immunostimulants | NA |
| Research programme: sirtuin targeted therapeutics for respiratory viral infections | Evrys Bio | Preclinical | Sirtuin modulators | Oral |
Request for Sample to know more @ Respiratory Syncytial Virus Infection Pipeline Analysis, Key Companies, and Futuristic Trends
Respiratory Syncytial Virus Therapeutic Assessment
The Respiratory Syncytial Virus Infection Pipeline report presents a complete view of the Respiratory Syncytial Virus emerging novel pipeline therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.
By Product Type
- Mono
- Combination
By Stage
- Discovery
- Preclinical
- Phase I
- Phase II
- Phase III
- Pre-registration
By Molecule Type
- Gene therapy
- Stem cell therapy
- Small molecules
By Route of Administration
- Oral
- Intravenous
- Inhalation
- Subcutaneous
By Mechanism of Action
- Protease Inhibitors
- Immunomodulatory
- Immunostimulants
- Sirtuin modulators
- Immunologic cytotoxicity; T lymphocyte replacements
- CD8 positive T lymphocyte stimulants
- Viral fusion protein inhibitors
By Targets
- Protease Inhibitors
- Immune system
Scope of Respiratory Syncytial Virus Infection Pipeline Report
- Coverage: Global
- Major Players: 50+ Key Players
- Prominent Players: Virometix, ReViral Ltd, Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. Codagenix, Inc, ModernaTX, Inc., Meissa Vaccines, Inc., Vaxart, Inc., Enanta Pharmaceuticals, MedImmune LLC (AstraZeneca), GlaxoSmithKline, Pfizer, Janssen Sciences Ireland UC, Icosavax, Inc., Ark Biosciences, Bavarian Nordic, Kidswell Bio, Evrys Bio, ReViral Ltd, Sanofi, Daiichi Sankyo, Codagenix, Inc., Cidara Therapeutics, clover biopharmaceuticals, Alios BioPharma, Allovir, Airway Therapeutics, and others.
- Key Respiratory Syncytial Virus Infection Pipeline Therapies: RSV-F, V-306, CodaVax-RSV, mRNA-1345, MV-012-968, RV521, BARS13, EDP-938, MEDI8897, RSV MAT, RSVpreF, JNJ-53718678, RSV vaccine, ALVR106, V-306, CodaVax-RSV, mRNA-1345, Research program: sirtuin targeted therapeutics for respiratory viral infections and others.
Table of Contents
| 1 | Introduction |
| 2 | Executive Summary |
| 3 | Respiratory Syncytial Virus Overview |
| 4 | RSV Analytical Perspective In-depth Commercial Assessment |
| 5 | Pipeline Therapeutics |
| 6 | Late Stage Products (Phase III) |
| 7 | Mid Stage Products (Phase II) |
| 8 | Early Stage Products (Phase I) |
| 9 | Therapeutic Assessment |
| 10 | Inactive Products |
| 11 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 12 | Respiratory Syncytial Virus Infection Key Companies |
| 13 | Respiratory Syncytial Virus Infection Key Products |
| 14 | Respiratory Syncytial Virus Infection Unmet Needs |
| 15 | Respiratory Syncytial Virus Infection Market Drivers and Barriers |
| 16 | RSV Infection Future Perspectives and Conclusion |
| 17 | Respiratory Syncytial Virus: Analyst Views |
| 18 | Appendix |
| 19 | About DelveInsight |
Learn more about the report offerings @ Respiratory Syncytial Virus Drug Pipeline Therapies, Novel Drug Delivery Platforms, and Emerging Trends
Audit the market before venturing with DelveInsight's Due Diligence Services
Related Reports
Respiratory Syncytial Virus Market
DelveInsight's "Respiratory Syncytial Virus (RSV) Market Insight, Epidemiology and Market Forecast -2031" report.
Respiratory Distress Market
DelveInsight's "Acute respiratory distress syndrome (ARDS) – Pipeline Insights, 2021" report
Severe Acute Respiratory Syndrome (SARS) Coronavirus Market
DelveInsight's "Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Market Insights, Epidemiology, and Market Forecast-2030" report
Middle East Respiratory Market
DelveInsight's "Middle East Respiratory Syndrome – Pipeline Insight, 2021" report.
Bacterial Vaginosis Market
DelveInsight's "Bacterial Vaginosis - Market Insights, Epidemiology, and Market Forecast-2030" report.
Candidemia Market
DelveInsight’s ‘Candidemia – Market Insights, Epidemiology, and Market Forecast—2030’ report.
Browse through our Blog Posts
Artificial intelligence and robotics are the two technologies that have shown the potential to address and provide solutions to many contemporary issues. Over the past three-four decades, robots have been used in sectors such as laboratory research, earth and space exploration, transport, and many more.
With at least half of the world's population as women and over 100 startups leveraging technology to bring novel devices to help women through different biological stages such as menstruation, pregnancy, breastfeeding, and others, the FemTech market offers ample growth opportunities.
The contribution of key pharma companies, such as 9 Meters Biopharma, ImmunogenX, Provention Bio, Cour Pharmaceuticals/Takeda, Precigen ActoBio, Falk Pharma, and Zedira is significant in driving Celiac disease market size.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News